Reply To: Adjuvant Immunotherapy in stage IIIA patients

[Anonymous]

Such an interesting discussion.

Another factor that is influencing this group of patients is the results from the MSLT-II trial which demonstrated no increased benefit on overall survival for patients with microscopic disease undergoing completion lymph node dissection. From a practical standpoint, this potentially means that more patients will be classified as Stage IIIa now than previously. Therefore, it will continue to be a detailed conversation with patients about the role of adjuvant therapy in that setting.